Celldex Therapeutics Inc. [NASDAQ: CLDX] price surged by 6.85 percent to reach at $0.83.
A sum of 1322175 shares traded at recent session while its average daily volume was at 831.93K shares. Celldex Therapeutics Inc. shares reached a high of $13.1199 and dropped to a low of $12.11 until finishing in the latest session at $12.94.
The one-year CLDX stock forecast points to a potential upside of 23.88. The average equity rating for CLDX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Celldex Therapeutics Inc. [CLDX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CLDX shares is $17.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CLDX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Celldex Therapeutics Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on February 21, 2020. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price to Buy. The new note on the price target was released on August 01, 2017, representing the official price target for Celldex Therapeutics Inc. stock.
The Average True Range (ATR) for Celldex Therapeutics Inc. is set at 0.91, with the Price to Sales ratio for CLDX stock in the period of the last 12 months amounting to 107.70. The Price to Book ratio for the last quarter was 1.20, with the Price to Cash per share for the same quarter was set at 5.65.
CLDX Stock Performance Analysis:
Celldex Therapeutics Inc. [CLDX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 7.74. With this latest performance, CLDX shares gained by 11.46% in over the last four-week period, additionally plugging by 734.84% over the last 6 months – not to mention a rise of 415.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CLDX stock in for the last two-week period is set at 59.35, with the RSI for the last a single of trading hit 63.61, and the three-weeks RSI is set at 58.87 for Celldex Therapeutics Inc. [CLDX]. The present Moving Average for the last 50 days of trading for this stock 11.34, while it was recorded at 12.23 for the last single week of trading, and 5.53 for the last 200 days.
Insight into Celldex Therapeutics Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Celldex Therapeutics Inc. [CLDX] shares currently have an operating margin of -1526.03. Celldex Therapeutics Inc.’s Net Margin is presently recorded at -1423.96.
Return on Total Capital for CLDX is now -49.18, given the latest momentum, and Return on Invested Capital for the company is -46.30. Return on Equity for this stock declined to -46.66, with Return on Assets sitting at -36.51. When it comes to the capital structure of this company, Celldex Therapeutics Inc. [CLDX] has a Total Debt to Total Equity ratio set at 3.89. Additionally, CLDX Total Debt to Total Capital is recorded at 3.74, with Total Debt to Total Assets ending up at 2.97. Long-Term Debt to Equity for the company is recorded at 1.82, with the Long-Term Debt to Total Capital now at 1.75.
Reflecting on the efficiency of the workforce at the company, Celldex Therapeutics Inc. [CLDX] managed to generate an average of -$391,369 per employee. Receivables Turnover for the company is 1.60 with a Total Asset Turnover recorded at a value of 0.03.Celldex Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 19.30 and a Current Ratio set at 19.30.
CLDX Stock EPS
With the latest financial reports released by the company, Celldex Therapeutics Inc. posted -0.75/share EPS, while the average EPS was predicted by analysts to be reported at -0.84/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 10.70%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CLDX.
Celldex Therapeutics Inc. [CLDX] Insider Position Details
There are presently around $359 million, or 72.40% of CLDX stock, in the hands of institutional investors. The top three institutional holders of CLDX stocks are: BVF INC/IL with ownership of 2,740,000, which is approximately New of the company’s market cap and around 0.10% of the total institutional ownership; RTW INVESTMENTS, LP, holding 2,610,000 shares of the stock with an approximate value of $33.77 million in CLDX stocks shares; and LOGOS GLOBAL MANAGEMENT LP, currently with $25.88 million in CLDX stock with ownership of nearly New of the company’s market capitalization.
Positions in Celldex Therapeutics Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 51 institutional holders increased their position in Celldex Therapeutics Inc. [NASDAQ:CLDX] by around 24,220,367 shares. Additionally, 19 investors decreased positions by around 459,777 shares, while 13 investors held positions by with 3,054,213 shares. The mentioned changes placed institutional holdings at 27,734,357 shares, according to the latest SEC report filing. CLDX stock had 39 new institutional investments in for a total of 22,799,625 shares, while 8 institutional investors sold positions of 102,860 shares during the same period.